{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:54:03Z","timestamp":1781664843174,"version":"3.54.5"},"reference-count":41,"publisher":"Norwegian Medical Association","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2011,10,4]]},"DOI":"10.4045\/tidsskr.10.1116","type":"journal-article","created":{"date-parts":[[2011,10,5]],"date-time":"2011-10-05T08:52:32Z","timestamp":1317804752000},"page":"1893-6","source":"Crossref","is-referenced-by-count":2,"title":["Denosumab for behandling av postmenopausal osteoporose"],"prefix":"10.4045","volume":"131","author":[{"given":"Unni","family":"Syversen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan I.","family":"Halse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Geisler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik Fink","family":"Eriksen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","doi-asserted-by":"crossref","unstructured":"Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther 2006; 28: 151\u2009\u2013\u200973. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16678639&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.clinthera.2006.02.007","DOI":"10.1016\/j.clinthera.2006.02.007"},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Syversen U, Halse JI. Bisfosfonatbehandling av osteoporose og andre skjelettsykdommer. Tidsskr Nor Legeforen 2011; 131: 244-7.","DOI":"10.4045\/tidsskr.09.0470"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Lyles KW, Colon-Emeric CS, Magaziner JS et al. Zoledronic acid in reducing clinical fracture and mortality after hip fracture. N Engl J Med 2007; 357: 1799\u2009\u2013\u2009809. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17878149&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa074941","DOI":"10.1056\/NEJMoa074941"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Simonet WS, Lacey DL, Dunstan CR et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 1997; 89: 309\u2009\u2013\u200919. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9108485&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0092-8674(00)80209-3","DOI":"10.1016\/S0092-8674(00)80209-3"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Tsuda E, Goto M, Mochizuki SI et al. Isolation of a\u00a0novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 1997; 234: 137\u2009\u2013\u200942. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9168977&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1006\/bbrc.1997.6603","DOI":"10.1006\/bbrc.1997.6603"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998; 93: 165\u2009\u2013\u200976. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9568710&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/S0092-8674(00)81569-X","DOI":"10.1016\/S0092-8674(00)81569-X"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Sattler AM, Schoppet M, Schaefer JR et al. Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. Calcif Tissue Int 2004; 74: 103\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14523602&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00223-003-0011-y","DOI":"10.1007\/s00223-003-0011-y"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Rogers A, Eastell R. Circulating osteoprotegerin and receptor activator for nuclear factor kappaB ligand: clinical utility in metabolic bone disease assessment. J Clin Endocrinol Metab 2005; 90: 6323\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16105967&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1210\/jc.2005-0794","DOI":"10.1210\/jc.2005-0794"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Chambers TJ. The cellular basis of bone resorption. Clin Orthop Relat Res 1980; 151: 283\u2009\u2013\u200993. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7418318&dopt=Abstract","DOI":"10.1097\/00003086-198009000-00039"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Yasuda H, Shima N, Nakagawa N et al. Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL. Proc Natl Acad Sci USA 1998; 95: 3597\u2009\u2013\u2009602. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9520411&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1073\/pnas.95.7.3597","DOI":"10.1073\/pnas.95.7.3597"},{"key":"ref=11","doi-asserted-by":"crossref","unstructured":"Kearns AE, Khosla S, Kostenuik PJ. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. Endocr Rev 2008; 29: 155\u2009\u2013\u200992. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18057140&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1210\/er.2007-0014","DOI":"10.1210\/er.2007-0014"},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Ueland T, Yndestad A, \u00d8ie E et al. Dysregulated osteoprotegerin\/RANK ligand\/RANK axis in clinical and experimental heart failure. Circulation 2005; 111: 2461\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15883214&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1161\/01.CIR.0000165119.62099.14","DOI":"10.1161\/01.CIR.0000165119.62099.14"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Vik A, Mathiesen EB, Brox J et al. Relation between serum osteoprotegerin and carotid intima media thickness in a general population \u2013 the Troms\u00f8 Study. J Thromb Haemost 2010; 8: 2133\u2009\u2013\u20099.","DOI":"10.1111\/j.1538-7836.2010.03990.x"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Pedersen ER, Ueland T, Seifert R et al. Serum osteoprotegerin levels and long-term prognosis in\u00a0patients with stable angina pectoris. Atherosclerosis 2010; 212: 644\u2009\u2013\u20099.","DOI":"10.1016\/j.atherosclerosis.2010.06.027"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Baud\u2019huin M, Lamoureux F, Duplomb L et al. RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases. Cell Mol Life Sci 2007; 64: 2334\u2009\u2013\u200950. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17530461&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00018-007-7104-0","DOI":"10.1007\/s00018-007-7104-0"},{"key":"ref=16","doi-asserted-by":"crossref","unstructured":"Naylor KE, Rogers A, Fraser RB et al. Serum osteoprotegerin as a determinant of bone metabolism in a longitudinal study of human pregnancy and lactation. J Clin Endocrinol Metab 2003; 88: 5361\u2009\u2013\u20095. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=14602774&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1210\/jc.2003-030486","DOI":"10.1210\/jc.2003-030486"},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"J\u00f8rgensen L, Vik A, Emaus N et al. Bone loss in relation to serum levels of osteoprotegerin and nuclear factor-kappaB ligand: the Troms\u00f8 Study. Osteoporos Int 2010; 21: 931\u2009\u2013\u20098. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19701599&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-009-1035-6","DOI":"10.1007\/s00198-009-1035-6"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"Bekker PJ, Holloway DL, Rasmussen AS et al. A\u00a0single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 2004; 19: 1059\u2009\u2013\u200966. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15176987&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/JBMR.040305","DOI":"10.1359\/JBMR.040305"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"McClung MR, Lewiecki EM, Cohen SB et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006; 354: 821\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16495394&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa044459","DOI":"10.1056\/NEJMoa044459"},{"key":"ref=20","doi-asserted-by":"crossref","unstructured":"Lewiecki EM, Miller PD, McClung MR et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007; 22:\u00a01832\u2009\u2013\u200941. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17708711&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/jbmr.070809","DOI":"10.1359\/jbmr.070809"},{"key":"ref=21","doi-asserted-by":"crossref","unstructured":"Brown JP, Prince RL, Deal C et al. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 2009; 24: 153\u2009\u2013\u200961. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18767928&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1359\/jbmr.0809010","DOI":"10.1016\/S0084-3741(09)79335-7"},{"key":"ref=22","doi-asserted-by":"crossref","unstructured":"Cummings SR, San Martin J, McClung MR et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J\u00a0Med 2009; 361: 756\u2009\u2013\u200965. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19671655&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa0809493","DOI":"10.1056\/NEJMoa0809493"},{"key":"ref=23","doi-asserted-by":"crossref","unstructured":"Baron R, Ferrari S, Russell RG. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 2011; 48: 677\u2009\u2013\u200992.","DOI":"10.1016\/j.bone.2010.11.020"},{"key":"ref=24","doi-asserted-by":"crossref","unstructured":"Genant HK, Engelke K, Hanley DA et al. Denosumab improves density and strength parameters as measured by QCT of the radius in postmenopausal women with low bone mineral density. Bone 2010; 47: 131\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20399288&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.bone.2010.04.594","DOI":"10.1016\/j.bone.2010.04.594"},{"key":"ref=25","doi-asserted-by":"crossref","unstructured":"Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809\u2009\u2013\u200922. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17476007&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa067312","DOI":"10.1056\/NEJMoa067312"},{"key":"ref=26","doi-asserted-by":"crossref","unstructured":"Reid IR, Miller PD, Brown JP et al. Effects of denosumab on bone histomorphometry: the FREEDOM and STAND studies. J Bone Miner Res 2010; 25: 2256\u2009\u2013\u200965. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20533525&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/jbmr.149","DOI":"10.1002\/jbmr.149"},{"key":"ref=27","doi-asserted-by":"crossref","unstructured":"Vallet S, Smith MR, Raje N. Novel bone-targeted strategies in oncology. Clin Cancer Res 2010; 16: 4084\u2009\u2013\u200993. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20643782&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-10-0600","DOI":"10.1158\/1078-0432.CCR-10-0600"},{"key":"ref=28","unstructured":"Norsk bryst cancer gruppe Adjuvant behandling, 1.\u00a0juli 2009. www.nbcg.no (8.4.2011)."},{"key":"ref=29","doi-asserted-by":"crossref","unstructured":"Gnant M. Can oral bisphosphonates really reduce the risk of breast cancer in healthy women? J Clin Oncol 2010; 28: 3548\u2009\u2013\u200951. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20567005&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.29.6327","DOI":"10.1200\/JCO.2010.29.6327"},{"key":"ref=30","doi-asserted-by":"crossref","unstructured":"Smith MR, Egerdie B, Hern\u00e1ndez Toriz N et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009; 361: 745\u2009\u2013\u200955. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19671656&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1056\/NEJMoa0809003","DOI":"10.1056\/NEJMoa0809003"},{"key":"ref=31","doi-asserted-by":"crossref","unstructured":"Fizazi K, Bosserman L, Gao G et al. Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial. J Urol 2009; 182: 509\u2009\u2013\u2009516. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19524963&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.juro.2009.04.023","DOI":"10.1016\/j.juro.2009.04.023"},{"key":"ref=32","doi-asserted-by":"crossref","unstructured":"Ellis GK, Bone HG, Chlebowski R et al. Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 2008; 26: 4875\u2009\u2013\u200982. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18725648&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2008.16.3832","DOI":"10.1200\/JCO.2008.16.3832"},{"key":"ref=33","doi-asserted-by":"crossref","unstructured":"Lipton A, Steger GG, Figueroa J et al. Extended efficacy and safety of denosumab in breast cancer patients with bone metastases not receiving prior bisphosphonate therapy. Clin Cancer Res 2008; 14:\u00a06690\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18927312&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1158\/1078-0432.CCR-07-5234","DOI":"10.1158\/1078-0432.CCR-07-5234"},{"key":"ref=34","doi-asserted-by":"crossref","unstructured":"Vij R, Horvath N, Spencer A et al. An open-label, phase 2 trial of denosumab in the treatment of relapsed or plateau-phase multiple myeloma. Am\u00a0J Hematol 2009; 84: 650\u2009\u2013\u20096. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19714603&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/ajh.21509","DOI":"10.1002\/ajh.21509"},{"key":"ref=35","doi-asserted-by":"crossref","unstructured":"Stopeck AT, Lipton A, Body JJ et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132\u2009\u2013\u20099. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=21060033&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1200\/JCO.2010.29.7101","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"ref=36","doi-asserted-by":"crossref","unstructured":"Cohen SB, Dore RK, Lane NE et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008; 58: 1299\u2009\u2013\u2009309. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=18438830&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/art.23417","DOI":"10.1002\/art.23417"},{"key":"ref=37","doi-asserted-by":"crossref","unstructured":"Deodhar A, Dore RK, Mandel D et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. Arthritis Care Res (Hoboken) 2010; 62: 569\u2009\u2013\u200974. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20391513&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1002\/acr.20004","DOI":"10.1002\/acr.20004"},{"key":"ref=38","doi-asserted-by":"crossref","unstructured":"Taylor KH, Middlefell LS, Mizen KD. Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 2010; 48: 221\u2009\u2013\u20093. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=19836866&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.bjoms.2009.08.030","DOI":"10.1016\/j.bjoms.2009.08.030"},{"key":"ref=39","doi-asserted-by":"crossref","unstructured":"Aghaloo TL, Felsenfeld AL, Tetradis S. Osteonecrosis of the jaw in a patient on Denosumab. J\u00a0Oral Maxillofac Surg 2010; 68: 959\u2009\u2013\u200963. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=20149510&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1016\/j.joms.2009.10.010","DOI":"10.1016\/j.joms.2009.10.010"},{"key":"ref=40","doi-asserted-by":"crossref","unstructured":"Kendler DL, McClung MR, Freemantle N et al. Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate. Osteoporos Int 2011; 22: 1725\u2009\u2013\u200935.","DOI":"10.1007\/s00198-010-1378-z"},{"key":"ref=41","doi-asserted-by":"crossref","unstructured":"Cramer JA, Gold DT, Silverman SL et al. A systematic review of persistence and compliance with bisphosphonates for osteoporosis. Osteoporos Int M2007; 18: 1023\u2009\u2013\u200931. PubMed: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=17308956&dopt=Abstract, Crossref: http:\/\/dx.doi.org\/10.1007\/s00198-006-0322-8","DOI":"10.1007\/s00198-006-0322-8"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T02:11:47Z","timestamp":1781662307000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2011\/10\/oversiktsartikkel\/denosumab-behandling-av-postmenopausal-osteoporose"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,4]]},"references-count":41,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2011,10,4]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.10.1116","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,4]]}}}